Mediste Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 17-12-2024
- Paid Up Capital ₹ 0.75 M
as on 17-12-2024
- Company Age 7 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 4.42 Cr
as on 17-12-2024
- Revenue 96.10%
(FY 2022)
- Profit 97.61%
(FY 2022)
- Ebitda 50.93%
(FY 2022)
- Net Worth 74.08%
(FY 2022)
- Total Assets 25.48%
(FY 2022)
About Mediste Pharmaceutical
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.75 M.
The company currently has active open charges totaling ₹4.42 Cr.
Shitiz Sukhija, Prem Madan, and Rohit Diwan serve as directors at the Company.
- CIN/LLPIN
U74999DL2017PTC320020
- Company No.
320020
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Jun 2017
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Mediste Pharmaceutical?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shitiz Sukhija  | Director | 09-Jul-2018 | Current |
| Prem Madan | Director | 30-Jun-2017 | Current |
| Rohit Diwan | Director | 30-Jun-2017 | Current |
Financial Performance and Corporate Structure Insights of Mediste Pharmaceutical.
Mediste Pharmaceutical Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 96.1% increase. The company also saw a substantial improvement in profitability, with a 97.61% increase in profit. The company's net worth Soared by an impressive increase of 74.08%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Mediste Pharmaceutical?
In 2022, Mediste Pharmaceutical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Millennium City Developers Private LimitedActive 4 years 10 months
Shitiz Sukhija is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 10 Jan 2024 | ₹4.30 Cr | Open |
Hdfc Bank Limited Creation Date: 19 Nov 2020 | ₹1.21 M | Open |
How Many Employees Work at Mediste Pharmaceutical?
Unlock and access historical data on people associated with Mediste Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mediste Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mediste Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
